GlassScriptPhysician profile
Kathleen A Long
NPI 1043215403
$2,099.59
in general payments reported to CMS, 2019-2025
33 companies · $57.56 in 2025
The $57.56 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $397 · 2021: $382 · 2024: $60.29 · 2025: $57.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $117.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $307.15 | 2019-2021 | |
| Amgen INC. | $197.74 | 2019-2021 | |
| Seagen INC. | $149.51 | 2019-2021 | |
| Genentech USA, INC. | $135.26 | 2019-2021 | |
| Abbvie INC. | $117.85 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $109.58 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $109.18 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $85.29 | 2019-2021 | |
| Celgene Corporation | $73.86 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $73.03 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $68.93 | 2019-2020 | |
| Genzyme Corporation | $67.17 | 2019-2020 | |
| Janssen Biotech, INC. | $63.57 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $49.38 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $41.86 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $37.34 | 2019-2020 | |
| Incyte Corporation | $36.19 | 2019-2020 | |
| Daiichi Sankyo INC. | $35.75 | 2020 | |
| Clovis Oncology, INC. | $35.45 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $35.18 | 2019 | |
| Tesaro, INC. | $34.93 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.03 | 2019 | |
| Deciphera Pharmaceuticals INC. | $28.15 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $24.80 | 2019 | |
| Tersera Therapeutics LLC | $24.06 | 2019 | |
| Puma Biotechnology, INC. | $20.94 | 2019 | |
| Glaxosmithkline, LLC. | $19.65 | 2021 | |
| Partner Therapeutics, INC. | $19.14 | 2019 | |
| Eisai INC. | $18.19 | 2019 | |
| Verastem, INC. | $15.75 | 2020 | |
| Lilly USA, LLC | $15.47 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.72 | 2019 | |
| Array Biopharma INC | $3.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.